KalVista Pharmaceuticals (KALV) Other Accumulated Expenses (2016 - 2025)
KalVista Pharmaceuticals recorded quarterly Other Accumulated Expenses of $681000.0 in Q3 2025, down 15.51% quarter-over-quarter from $806000.0 in Q2 2025, and down 48.17% year-over-year from $1.3 million in Q3 2024.
KalVista Pharmaceuticals' Other Accumulated Expenses history runs 10 years deep, the most recent figure standing at $681000.0 for Q3 2025.
- In Q3 2025, Other Accumulated Expenses fell 48.17% year-over-year to $681000.0; the TTM figure through Jul 2025 stood at $681000.0 (down 48.17% YoY), while the FY2025 annual figure was $806000.0, up 218.58% from the prior year.
- Other Accumulated Expenses came in at $681000.0 for Q3 2025 at KalVista Pharmaceuticals, down from $806000.0 in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $1.3 million in Q3 2024 to a low of $124000.0 in Q1 2021.
- A 5-year average of $365000.0 and a median of $253000.0 in 2024 frame the typical range for Other Accumulated Expenses.
- Across the five-year window, Other Accumulated Expenses sank 55.4% in 2021 and surged 787.84% in 2024, its largest moves.
- KalVista Pharmaceuticals' Other Accumulated Expenses stood at $190000.0 in 2021, then rose by 17.89% to $224000.0 in 2022, then surged by 40.18% to $314000.0 in 2023, then jumped by 120.7% to $693000.0 in 2024, then declined by 1.73% to $681000.0 in 2025.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $681000.0, $806000.0, and $693000.0 for Q3 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | 681,000.00 |
| Apr 30, 2025 | 806,000.00 |
| Dec 31, 2024 | 693,000.00 |
| Oct 31, 2024 | 279,000.00 |
| Jul 31, 2024 | 1.31 Mn |
| Apr 30, 2024 | 253,000.00 |
| Jan 31, 2024 | 135,000.00 |
| Oct 31, 2023 | 314,000.00 |
| Jul 31, 2023 | 148,000.00 |
| Apr 30, 2023 | 198,000.00 |
| Jan 31, 2023 | 293,000.00 |
| Oct 31, 2022 | 224,000.00 |
| Jul 31, 2022 | 218,000.00 |
| Apr 30, 2022 | 308,000.00 |
| Jan 31, 2022 | 187,000.00 |
| Oct 31, 2021 | 190,000.00 |
| Jul 31, 2021 | 180,000.00 |
| Apr 30, 2021 | 390,000.00 |
| Jan 31, 2021 | 124,000.00 |
| Oct 31, 2020 | 78,000.00 |
| Jul 31, 2020 | 47,000.00 |
| Apr 30, 2020 | 128,000.00 |
| Jan 31, 2020 | 278,000.00 |
| Oct 31, 2019 | 216,000.00 |
| Jul 31, 2019 | 261,000.00 |
| Apr 30, 2019 | 447,000.00 |
| Jan 31, 2019 | 233,000.00 |
| Oct 31, 2018 | 142,000.00 |
| Jul 31, 2018 | 161,000.00 |
| Apr 30, 2018 | 338,000.00 |
| Jan 31, 2018 | 253,000.00 |
| Oct 31, 2017 | 142,000.00 |
| Jul 31, 2017 | 538,000.00 |
| Apr 30, 2017 | 71,000.00 |
| Jan 31, 2017 | 466,000.00 |
| Mar 31, 2016 | 49,000.00 |